文献速递妇科

对乙酰氨基酚使用与上皮性卵巢癌风险:一项全国性巢式病例对照研究

Paracetamol use and risk of epithelial ovarian cancer: A nationwide nested case-control study.
PubMed 文献 · BJOG · 2023-08-07

在丹麦女性人群中开展的全国性巢式病例对照研究,纳入2000至2019年确诊的9589例上皮性卵巢癌(EOC)病例,按年龄匹配383549名随机对照。调整潜在混杂因素后,曾使用对乙酰氨基酚与EOC风险降低相关(OR 0.92,95% CI 0.87-0.97),且风险随累积剂量和剂量强度增加而进一步下降,呈剂量-反应关系。作者认为需未来研究验证该发现并探究其机制。

要点

  • 曾使用对乙酰氨基酚与上皮性卵巢癌风险降低相关(OR 0.92,95% CI 0.87-0.97)。
  • 该关联仅在近期使用者中显著(OR 0.89,95% CI 0.84-0.95)。
  • 高累积剂量组和高剂量强度组风险分别降低13%(OR 0.87,95% CI 0.80-0.94)和14%(OR 0.86,95% CI 0.79-0.93)。

核心结论

  • 对乙酰氨基酚使用与上皮性卵巢癌风险降低相关,且呈剂量-反应关系。
  • 作者指出需未来研究验证该发现并探究该关联背后的机制。

研究设计与样本

  • 全国性巢式病例对照研究,纳入丹麦女性人群。
  • 2000至2019年确诊的9589例上皮性卵巢癌病例,采用风险集抽样按年龄匹配383549名随机选择的女性对照。
  • 对乙酰氨基酚使用、生育史、用药史和手术史从丹麦国家登记处获取;使用定义为索引日期前至少2次处方且最长追溯1年,并按近期性、持续时间、累积剂量和剂量强度分类。
  • 采用条件logistic回归估计对乙酰氨基酚与上皮性卵巢癌风险关联的比值比(OR)和95%置信区间(CI),分析总体及按组织学亚型。

主要发现

  • 调整潜在混杂因素后,曾使用对乙酰氨基酚与上皮性卵巢癌风险降低相关(OR 0.92,95% CI 0.87-0.97)。
  • 该关联仅在近期使用者中显著(OR 0.89,95% CI 0.84-0.95)。
  • 风险随累积剂量和剂量强度增加而进一步下降:高累积剂量组风险降低13%(OR 0.87,95% CI 0.80-0.94),高剂量强度组风险降低14%(OR 0.86,95% CI 0.79-0.93)。
  • 组织学亚型分析中,曾使用对乙酰氨基酚的风险降低在浆液性和透明细胞肿瘤中最为明显。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 作者指出需未来研究验证该发现并探究该关联背后的机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether paracetamol use is associated with a reduced risk of epithelial ovarian cancer (EOC). DESIGN: A nationwide nested case-control study. SETTING: Danish female population. POPULATION: A total of 9589 EOC cases diagnosed from 2000 to 2019 were age-matched with 383 549 randomly selected female controls using risk set sampling. METHODS: Paracetamol use, reproductive history, history of medication and history of surgery were retrieved from Danish national registers. Paracetamol use was defined as at least two prescriptions for up to 1 year before the index date, and was further classified according to recency, duration, cumulative dose and intensity of dose. MAIN OUTCOME MEASURES: Conditional logistic regression was used to estimate odds ratios and 95% confidence intervals for the association between paracetamol and EOC risk, overall and by histological subtypes. RESULTS: 'Ever' use of paracetamol was associated with a reduced EOC risk after adjusting for potential confounding factors (OR 0.92, 95% CI 0.87-0.97). The association was only significant among recent users (OR 0.89, 95% CI 0.84-0.95). The risk declined further with the increasing level of cumulative dose and intensity; women from the group with a high cumulative dose and a high intensity had a 13% (OR 0.87, 95% CI 0.80-0.94) and 14% (OR 0.86, 95% CI 0.79-0.93) reduced risk, respectively. In the histological subtype analysis, reduced risk with 'ever' use was most pronounced for serous and clear cell tumours. CONCLUSIONS: Paracetamol use was associated with a decreased risk of EOC in a dose-response manner. Future studies are needed to validate the findings and investigate the mechanisms behind the association.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Zheng G, Faber MT, Baandrup L, et al. Paracetamol use and risk of epithelial ovarian cancer: A nationwide nested case-control study. BJOG. 2023. PMID: 37551038. doi:10.1111/1471-0528.17632

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。